Compare Stocks: ASMB, CMPS, ANIP, and URGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$72.28 -1.2%	$73.06	$69.58 ▼ $95.57	$1.66B	0.5	377,462 shs	88,898 shs
ASMB Assembly Biosciences	$20.13 -3.5%	$26.41	$19.30 ▼ $39.71	$409.75M	1.15	190,529 shs	65,456 shs
CMPS Compass Pathways	$11.42 -6.3%	$12.95	$4.88 ▼ $15.87	$1.58B	2.55	3.41 million shs	1.45 million shs
URGN Urogen Pharma	$32.67 -2.4%	$40.72	$16.50 ▼ $50.81	$1.59B	1.57	830,407 shs	461,376 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	+2.02%	-0.80%	+0.74%	-7.67%	-20.68%
ASMB Assembly Biosciences	+1.41%	+2.86%	-11.16%	-16.93%	-32.69%
CMPS Compass Pathways	-0.73%	+4.82%	-5.94%	+7.40%	+92.58%
URGN Urogen Pharma	-0.80%	-4.75%	-17.23%	-12.45%	+69.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$72.28 -1.2%	$73.06	$69.58 ▼ $95.57	$1.66B	0.5	377,462 shs	88,898 shs
ASMB Assembly Biosciences	$20.13 -3.5%	$26.41	$19.30 ▼ $39.71	$409.75M	1.15	190,529 shs	65,456 shs
CMPS Compass Pathways	$11.42 -6.3%	$12.95	$4.88 ▼ $15.87	$1.58B	2.55	3.41 million shs	1.45 million shs
URGN Urogen Pharma	$32.67 -2.4%	$40.72	$16.50 ▼ $50.81	$1.59B	1.57	830,407 shs	461,376 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	+2.02%	-0.80%	+0.74%	-7.67%	-20.68%
ASMB Assembly Biosciences	+1.41%	+2.86%	-11.16%	-16.93%	-32.69%
CMPS Compass Pathways	-0.73%	+4.82%	-5.94%	+7.40%	+92.58%
URGN Urogen Pharma	-0.80%	-4.75%	-17.23%	-12.45%	+69.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	2.43	Hold	$99.60	37.79% Upside
ASMB Assembly Biosciences	2.83	Moderate Buy	$47.50	136.02% Upside
CMPS Compass Pathways	2.88	Moderate Buy	$23.36	104.53% Upside
URGN Urogen Pharma	2.70	Moderate Buy	$52.38	60.32% Upside

Current Analyst Ratings Breakdown

Latest ASMB, CMPS, ANIP, and URGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/19/2026	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$75.00
10/15/2026	ASMB Assembly Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	CMPS Compass Pathways	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	URGN Urogen Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/23/2026	ANIP ANI Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Perform	$85.00
9/10/2026	URGN Urogen Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$56.00
9/9/2026	CMPS Compass Pathways	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/9/2026	ANIP ANI Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$104.00
9/1/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$53.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$52.00

(Data available from 10/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$883.37M	1.88	$10.01 per share	7.22	$24.03 per share	3.01
ASMB Assembly Biosciences	$72.30M	5.67	N/A	N/A	$13.04 per share	1.54
CMPS Compass Pathways	N/A	N/A	N/A	N/A	($0.55) per share	N/A
URGN Urogen Pharma	$188.73M	8.46	N/A	N/A	($2.25) per share	-14.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	$78.34M	$4.64	15.60	8.69	2.31	11.07%	27.37%	10.47%	11/5/2026 (Estimated)
ASMB Assembly Biosciences	-$6.12M	$1.02	19.73	402.50	N/A	-0.06%	-0.02%	-0.02%	11/9/2026 (Estimated)
CMPS Compass Pathways	-$287.86M	-$4.62	N/A	N/A	N/A	N/A	-49.63%	-13.08%	11/3/2026 (Estimated)
URGN Urogen Pharma	-$153.49M	-$1.98	N/A	10.21	N/A	-51.73%	N/A	-43.79%	11/4/2026 (Estimated)

Latest ASMB, CMPS, ANIP, and URGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	ASMB Assembly Biosciences	-$0.6550	N/A	N/A	N/A	$9.07 million	N/A
11/5/2026	Q3 2026	ANIP ANI Pharmaceuticals	$2.18	N/A	N/A	N/A	$280.26 million	N/A
11/4/2026	Q3 2026	URGN Urogen Pharma	$0.10	N/A	N/A	N/A	$89.83 million	N/A
11/3/2026	Q3 2026	CMPS Compass Pathways	-$0.34	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	ASMB Assembly Biosciences	-$0.7242	-$0.20	+$0.5242	-$0.20	$8.60 million	$13.37 million
8/7/2026	Q2 2026	ANIP ANI Pharmaceuticals	$2.04	$2.21	+$0.17	$1.05	$260.13 million	$266.04 million
8/5/2026	Q2 2026	CMPS Compass Pathways	-$0.3881	-$1.88	-$1.4919	-$1.88	N/A	N/A
8/5/2026	Q2 2026	URGN Urogen Pharma	-$0.2650	-$0.28	-$0.0150	-$0.28	$63.55 million	$72.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
CMPS Compass Pathways	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	0.99	2.91	2.41
ASMB Assembly Biosciences	N/A	13.99	13.99
CMPS Compass Pathways	0.60	1.30	1.30
URGN Urogen Pharma	N/A	3.80	3.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
ASMB Assembly Biosciences	19.92%
CMPS Compass Pathways	46.19%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	8.10%
ASMB Assembly Biosciences	3.50%
CMPS Compass Pathways	2.82%
URGN Urogen Pharma	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	970	22.97 million	21.11 million	Optionable
ASMB Assembly Biosciences	73	20.36 million	19.65 million	Optionable
CMPS Compass Pathways	156	138.48 million	134.57 million	Optionable
URGN Urogen Pharma	291	48.88 million	46.54 million	Optionable

ASMB, CMPS, ANIP, and URGN Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Urogen Pharma (URGN)

October 29 at 10:35 PM | theglobeandmail.com

Urogen Pharma (URGN) Projected to Announce Quarterly Earnings on Wednesday

October 29 at 7:10 AM | marketbeat.com

UroGen's Zusduri Offers Early Innings Opportunity, Oppenheimer Says

October 28 at 3:36 PM | finance.yahoo.com

UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer

October 28 at 10:35 AM | markets.businessinsider.com

UroGen Reports No High-Grade Disease Progression In Five-Year JELMYTO Follow-Up; Stock Down

October 28 at 10:35 AM | rttnews.com

UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer

October 28 at 8:00 AM | globenewswire.com

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

October 27 at 6:00 PM | globenewswire.com

Bender Robert & Associates Purchases New Stake in Urogen Pharma $URGN

October 22, 2026 | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Urogen Pharma (NASDAQ:URGN)

October 21, 2026 | americanbankingnews.com

Why UroGen Pharma (URGN) Is Getting Fresh Attention Now

October 20, 2026 | finance.yahoo.com

FDA accepts UGN-103 filing and UroGen Pharma stock trades at EUR 30.50

October 20, 2026 | ad-hoc-news.deA

UroGen Pharma Ltd. Announces FDA Acceptance Of The New Drug Application For UGN-103 For The Treatment Of Adults With Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive ...

October 19, 2026 | marketscreener.comM

UroGen Pharma Announces FDA Acceptance Of UGN-103 NDA For Review

October 19, 2026 | rttnews.com

UroGen Secures FDA NDA Acceptance For Investigational Bladder Cancer Therapy

October 19, 2026 | rttnews.com

UroGen Pharma Says FDA Accepts New Drug Application for UGN-103 in Bladder Cancer

October 19, 2026 | finance.yahoo.com

Urogen Pharma (NASDAQ:URGN) Stock Keeps "Buy" Rating at HC Wainwright

October 19, 2026 | marketbeat.com

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

October 19, 2026 | globenewswire.com

UroGen appoints Liz Barrett as CEO ahead of UroGen Pharma stock results

October 18, 2026 | ad-hoc-news.deA

UroGen Pharma: An Emerging GARP Stock

October 13, 2026 | seekingalpha.com

Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $52.38 According to Analysts

October 12, 2026 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) CFO Chris Degnan Sells 2,202 Shares of Stock

October 10, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB, CMPS, ANIP, and URGN Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$72.28 -0.88 (-1.20%)

As of 03:13 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Assembly Biosciences NASDAQ:ASMB

$20.12 -0.74 (-3.52%)

As of 03:12 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Compass Pathways NASDAQ:CMPS

$11.42 -0.77 (-6.32%)

As of 03:13 PM Eastern

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Urogen Pharma NASDAQ:URGN

$32.67 -0.81 (-2.42%)

As of 03:13 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASMB, CMPS, ANIP, and URGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASMB, CMPS, ANIP, and URGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASMB, CMPS, ANIP, and URGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB, CMPS, ANIP, and URGN Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

Assembly Biosciences NASDAQ:ASMB

Compass Pathways NASDAQ:CMPS

Urogen Pharma NASDAQ:URGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASMB, CMPS, ANIP, and URGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASMB, CMPS, ANIP, and URGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASMB, CMPS, ANIP, and URGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB, CMPS, ANIP, and URGN Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

Assembly Biosciences NASDAQ:ASMB

Compass Pathways NASDAQ:CMPS

Urogen Pharma NASDAQ:URGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools